Retroperitoneal operations, such as radical prostatectomy, often damage the cavernous nerve, resulting in a high incidence of erectile dysfunction. Although improved nerve-sparing techniques have reduced the incidence of nerve injury, and the administration of phosphodiesterase type 5 inhibitors has revolutionized the treatment of erectile dysfunction, this problem remains a considerable challenge. In recent years, scientists have focused on brain-derived neurotrophic factor and vascular endothelial growth factor in the treatment of cavernous nerve injury in rat models. Results showed that both compounds were capable of enhancing the regeneration of the cavernous nerve and that activation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway played a major role in the process. Keywords: brain-derived neurotrophic factor; erectile dysfunction; Janus kinase; signal transducer and activator of transcription; vascular endothelial growth factor INTRODUCTION Radical prostatectomy in prostate cancer patients and other retroperitoneal surgical operations, such as radical rectal cancer surgeries, often lead to cavernous nerve damage, resulting in a high incidence of erectile dysfunction (ED); this has opened a new field of ED treatment. Many investigators have tried to develop novel methods of reducing the incidence of ED. Walsh and colleagues 1 developed a nerve-sparing technique to preserve potency after radical prostatectomy and cystoprostatectomy. However, in their study of 250 patients, sexual potency was impaired by 37% in patients who underwent bilateral nerve-sparing prostatectomy. Although the use of phosphodiesterase type 5 inhibitors has revolutionized the treatment of ED, this complication after surgery persists.
INTRODUCTION
Radical prostatectomy in prostate cancer patients and other retroperitoneal surgical operations, such as radical rectal cancer surgeries, often lead to cavernous nerve damage, resulting in a high incidence of erectile dysfunction (ED); this has opened a new field of ED treatment. Many investigators have tried to develop novel methods of reducing the incidence of ED. Walsh and colleagues 1 developed a nerve-sparing technique to preserve potency after radical prostatectomy and cystoprostatectomy. However, in their study of 250 patients, sexual potency was impaired by 37% in patients who underwent bilateral nerve-sparing prostatectomy. Although the use of phosphodiesterase type 5 inhibitors has revolutionized the treatment of ED, this complication after surgery persists. 2 Many urologists focus on methods for reducing the likelihood of ED after surgery and accelerating regeneration of the cavernous nerve.
Although neuromodulatory therapy, which consists of neuroprotective and neurotrophic interventions, is based on the extremely limited intrinsic recovery ability of peripheral nerves, it has recently been proposed as the next breakthrough in cavernous nerve functional restoration. 3 The neurotrophins, including brain-derived neurotrophic factor (BDNF) and nerve growth factor, comprise a large family of closely related proteins that are expressed in a variety of cell types. They were first identified as survival factors for sympathetic and sensory neurons and were subsequently found to have a wide range of influences on cellular activities, including transfer signals as well as neuronal differentiation, development and regeneration. 4, 5 Neurotrophins regulate cell activities through PI-3 kinase (PI3K) cascades and a series of signalling pathways mediated by G proteins, such as Ras and Ras/ Rho. 6 In the past decade, pioneering researchers have embarked on a series of explorations of the mechanism of cavernous nerve regeneration with neurotrophins, especially BDNF and vascular endothelial growth factor (VEGF); this led to the discovery of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, which played an important role in promoting neurite growth in the major pelvic ganglion (MPG) in rat models. 7 The JAK/STAT pathway was first identified as the signal transduction pathway downstream of the cytokine receptors; these receptors, which are stimulated by cytokines, hormones, vasoactive agents and growth factors, lead to JAK phosphorylation and activation. Next, STAT binds to the activated receptors and is phosphorylated and translocated into the nucleus, where it acts as a transcription factor. 8 The JAK/STAT pathway plays a role in a large number of normal and abnormal physiological processes, including intestinal lineage differentiation, 9 human leukaemias and myeloproliferative disorders, 10 and endothelial cell migration and proliferation. Recently, there has been increasing evidence of an important role of the JAK/STAT pathway in peripheral nerve regeneration. 6, 11, 12 In this article, we focus on attempts to use BDNF and VEGF to promote the regeneration of the cavernous nerve after injury and examine the relationship between these growth factors and the JAK/ STAT pathway.
BDNF AND VEGF
BDNF is a member of the mammalian family of neurotrophins, which also includes nerve growth factor and neurotrophins 3, 4 and 5. In 1982, Barde and colleagues 13 initially identified BDNF on the basis of its survival-promoting effect on cultured chick embryonic dorsal root ganglion neurons. Since then, additional BDNF activities have been discovered. BDNF could also promote neuronal survival during development and prevent neuronal death in experimental neuropathy models. 14, 15 Recent studies have revealed that BDNF could provide neurotrophic support for a host of neuron types, such as peripheral sensory neurons and motor neurons. 13, 16, 17 Because of its wide range of activities, BDNF is being considered in the treatment of a variety of neurodegenerative diseases. 18 BDNF promotes cell survival through two types of receptors: high-affinity tyrosine kinase B (TrkB) receptors and low-affinity pan-neurotrophin 75 (p75) receptors. 19 Binding of the Src homology domain-containing adaptor protein to TrkB leads to the recruitment of growth factor receptor-bound protein-2 and subsequent activation of Ras; this in turn activates the PI3K, mitogen-activated extracellular signal-regulated kinase (MEK1/2) and extracellular signal-regulated kinase (ERK1/2) pathways. Ribosomal S6 kinase phosphorylates cAMP response element-binding protein and other transcription factors. PI3K directly regulates certain survival pathways by activating serine/ threonine protein kinase (Akt), which leads to neurogenesis. Another signalling pathway that is activated by TrkB involves phospholipase-Cc, which results in the activation of protein kinase C via inositol 1,4,5-trisphosphate and diacylglycerol; this promotes long-term cellular responses related to proliferation and migration ( Figure 1) .
VEGF is an extensive endothelial cell-specific mitogen in vitro and is capable of inducing angiogenesis in a variety of in vivo models. Brown's study 20, 21 showed that VEGF might have important and previously unsuspected roles in types of tissue other than the endothelium. Furthermore, Sondell et al. 22 revealed that VEGF acted as a neurotrophic factor and could stimulate axonal outgrowth through the flk-1 receptor (VEGF-R2). VEGF promotes nerve regeneration Figure 1 The activated TrkB receptor and the VEGF receptor recruit several specific small cytoplasmic signalling G proteins, including SHC, GRB2 and the Ras/Rho family; they are also involved in pathways regulated by MAPK, PI3K and ERK, evoking cellular responses that govern proliferation, migration and other processes. JAK activation occurs at cytokine-mediated receptors and subsequently results in the phosphorylation of STATs. To date, we have no evidence that BDNF and VEGF activate the JAK/STAT pathway by direct binding. Arrows indicate activation; T-shaped arrows indicate inhibition. Akt, serine/threonine protein kinase; BDNF, brainderived neurotrophic factor; Cks, cytokines; CREB, cAMP response element-binding protein; DAG, diacylglycerol; ERK, extracellular signal-regulated kinase; GRB2, growth factor receptor-bound protein-2; IP3, inositol 1,4,5-trisphosphate; JAK, Janus kinase; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated extracellular signal-regulated kinase; PKC, protein kinase C; PI3K, PI-3 kinase; PLC-c, phospholipase-Cc; RSK, ribosomal S6 kinase; STAT, signal transducer and activator of transcription; SHC, Src homology domain-containing adaptor protein; TrkB, tyrosine kinase B; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
mainly through the Ras/Raf pathway (Figure 1) . However, some other reports have demonstrated that VEGF-induced neuroprotection is mediated through an flk-1 receptor-dependent activation of the PI3K/Akt signalling pathway; 23 because of the evidence of motor neuron regeneration, 24 a more plausible hypothesis is that the PI3K/Akt pathway plays a key role in VEGF-mediated neurite outgrowth.
The ability of BDNF to prevent degeneration of neurons located in the MPG that contain neuronal nitric oxide synthase (NOS), along with its ability to enhance the recovery of erectile function in rat models of bilateral cavernous nerve injury, has been demonstrated using BDNF gene therapy with adeno-associated virus-mediated production of neurotrophic factors. 25 Additionally, the ability of VEGF to induce the isoforms of NOS (endothelial NOS and inducible NOS) in the penis after intracavernosal injection has been reported in rat models of ligated pudendal arteries. 26 The authors found that endothelial NOS was expressed in the endothelium and probably mediated the angiogenic process; inducible NOS was expressed in smooth muscle and might provide protection against ischemic injury. 26 The lack of neuronal NOS indicated that it might play an incidental role in the angiogenic or injury responses. Later, researchers showed that BDNF could enhance the regeneration of neuronal NOS-containing nerve fibres. 27, 28 In 2003, Lin et al. 12 first observed the function of VEGF and BDNF in enhancing the outgrowth of nerve fibres on cultured MPG in vitro in serum-free medium supplemented with VEGF (50 ng ml 21 ), BDNF, and neurotrophins 3 and 4 (each at a concentration of 20 ng ml 21 ). After 2 days of culture, the specimens were stained for NOS, tyrosine hydroxylase and acetylcholinesterase. Lin et al. 12 found that BDNF and VEGF were both capable of inducing fibres that express NOS, tyrosine hydroxylase and acetylcholinesterase.
Lee and colleagues 29 injected VEGF intracavernously to test its erectile restoration effect in rat models of traumatic arteriogenic ED. They ligated both internal iliac arteries in rats to create traumatic arteriogenic ED models and then injected VEGF (2 mg versus 4 mg) into the cavernosum. The results showed that VEGF treatment facilitated the recovery of erectile function compared with the shamoperated group. The recovery in the 4-mg group was more pronounced than in the 2-mg group. Recovery of neuronal NOS-positive nerve fibres was also noted after VEGF treatment. The responsible mechanism might involve the ability of VEGF to promote neovascularisation in ischemic tissues and possibly to exert neurotrophic effects. 12 Many study groups have made remarkable contributions to other clinical applications. The retrograde transport of BDNF from axons to the neuronal cell body provided a theoretical basis for many of these studies. 30 One group tried a new approach in which bilateral nerves were crushed with a haemostat for 2 min and then intracavernously injected with BDNF (600 ng/rat) and VEGF (4000 ng/rat) to investigate their function in nerve regeneration and recovery of erectile function. 31 They later suggested that the optimal dose of both factors for promoting MPG neurite growth was 25-50 ng ml 21 in the in vitro system. 32 Neurite growth from aged rats were not as robust as growth from tissue from younger rats, which indicates that future clinical trials might reveal important differences in the responsiveness of aged human tissue to these types of treatments. 32 
JAK/STAT PATHWAY
Research on interferons has found that they transduce signals through a new type of signalling pathway that involves activation of transcription factors at the cell membrane, now known as STATs. STATs are activated by the JAK family of protein tyrosine kinases. Subsequent studies identified four JAKs (Jak1, Jak2, Jak3 and Tyk2) [33] [34] [35] [36] and seven STATs [37] [38] [39] [40] [41] [42] [43] [44] (STATs 1, 2, 3, 4, 5a, 5b and 6), which are involved in a different signal transduction pathway mechanism. In mammals, the JAK/STAT pathway is becoming increasingly known as the principal signalling mechanism for a wide range of growth factors and cytokines; 45, 46 it plays an important role in cell proliferation, differentiation, migration and apoptosis. Any mutation of JAK/STAT will affect the activity of the pathway. 47, 48 In recent years, researchers have found that activation of the JAK/ STAT pathway can enhance the process of peripheral nerve regeneration. 6, 11, 12 STAT3 activation is central to the enhanced ability of neurons to grow and is implicated in accelerated axonal regeneration. 11 It has been shown that phosphorylation of STAT3 confers the ability to translocate into the nucleus, where it combines with genomic regulatory sequences and enhances the transcription of related genes. 49 Only a few genes have thus far been defined as targets of STAT3, including neuropeptide vasoactive intestinal peptide and c-Jun. [50] [51] [52] [53] The results of a study by Sheu et al. 54 suggested that the activation of the JAK/ STAT3 pathway might be related to axonal regeneration and the proliferation and migration of Schwann cells after sciatic nerve injury. After transection of cavernous nerves in rat models, the phosphorylation levels of STAT3 and STAT1 also increased significantly as compared with a control group (P,0.01). 55 As mentioned above, BDNF promotes neuronal survival and neurite outgrowth and prevents neuronal degeneration; most of the mechanisms and the specific signalling pathways remained unclear although some have already been identified, including Ras and cdc-42/ras/rho G protein families as well as the mitogen-activated protein kinase (MAPK), PI3K and phospholipase-Cc cascades. Although BDNF transfers signals into cells through the TrkB and p75 receptors, some reports showed no role for MAPK/ERK and PI3K in mature peripheral neuron regeneration. 56 Studies by Gallo et al. 57 and Liu and Snider 58 showed that maintenance of the protective effects of BDNF was independent of protein kinase A activity and a JAK2 inhibitor prevented the regenerative axonal response to a conditional lesion; this suggests the existence of an alternative JAK/STAT link between cytokine signalling and axon growth. To explore the mechanism of the neurite growth enhancement of explant MPG cultures, researchers 7 tried inhibitors of four candidate signalling pathways-MEK (U0126), PI3K (LY294002), protein kinase A (KT5720) and JAK/STAT (AG490)-supplemented with BDNF. The investigators found that AG490 significantly reduced BDNF-enhanced neurite growth as compared with the other pathways, which suggests that BDNF acts primarily via the JAK/STAT pathway to promote neurite growth in the rat MPG; they confirmed the findings in another study. 6 The researchers proposed that BDNF exerted its effect via the induction of phosphorylation of JAK2, STAT1 and STAT3. Increased expression of penile BDNF and upregulation of phosphorylated STAT1 and STAT3 in MPG were observed directly in response to cavernous nerve transection, 55 which provided better support for the theories described above. However, we do not yet know whether JAK/STAT is directly activated by BDNF. A more likely mechanism involves a secondary procedure; that is, Schwann cells are activated by BDNF and then modulate the local environment to enhance the regeneration process via the synthesis and release of surface cell adhesion molecules, extracellular matrix proteins and neurotrophic factors, which will ultimately activate the JAK/ STAT pathway. 59 The potential role of Schwann cells in BDNFmediated neurite outgrowth requires further investigation.
With regard to the interaction between the VEGF and JAK/STAT pathways, most studies have focused on their relationship to tumours 60, 61 or cellular invasiveness. 62 As yet, there is no evidence that supports a role for VEGF in promoting neurite outgrowth by directly activating the JAK/STAT pathway. VEGF may achieve its goal through its angiogenesis effect or by activating the JAK/STAT pathway by direct binding in a manner similar to that of the other neurotrophic factors. However, evidence that STAT3 activation elevates VEGF expression levels 62 could provide another possibility. The increased VEGF expression after cavernous nerve injury induced by elevated STAT3 phosphorylation levels 55 may further activate the JAK/STAT pathway. The VEGF and JAK/STAT pathways directly or indirectly interact with each other.
Despite abundant emerging evidence that the JAK/STAT pathway plays a central role in cavernous nerve regeneration after injury, the details of the mechanism remain unknown. The potential mechanisms and their overall effects on nerve regeneration require further investigation. Therapeutic advances will be developed when a better understanding of the JAK/STAT pathway is achieved. CONCLUSION VEGF and BDNF are both capable of enhancing regeneration of the cavernous nerve after injury. The JAK/STAT signalling pathway plays an important role in this process, and, although the mechanism needs to be elucidated in detail, it clearly represents a promising new molecular target for modulating nerve survival and regeneration.
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